The only update for patients with stage IV NSCLC without driver alterations is that patients who have HER2-overexpressing (IHC 3+) disease and good performance status can receive trastuzumab ...

Researchers reviewed the impact of prehabilitation on several surgery outcomes measures in patients with colorectal cancer.

Minimal residual disease negativity was achieved at a significantly higher rate with venetoclax-based therapies, supporting its role in CLL.

The dose of paclitaxel used in the new approach was 16-fold lower than that typically used in free paclitaxel, but with similar efficacy.

Mirvetuximab soravtansine improved overall survival, progression-free survival, second progression-free survival, and other outcomes.

Data suggest that adding an ARPI to standard care improves outcomes for most patients with mHSPC, but those benefits decrease with age.

A rare case has been reported of diffuse large B-cell lymphoma (DLBCL) presenting initially as cold agglutinin disease (CAD). The report, published in the Kaohsiung Journal of Medical Sciences, ...

According to investigators, there is no validated PSA-based endpoint to compare oncologic outcomes after radical prostatectomy and radiation therapy for localized prostate cancer.

HealthDay News — Children with congenital heart disease (CHD) have increased risk of developing cancer, according to a research letter published in the March 18 issue of Circulation.

It is imperative to align strategies that can prevent ovarian cancer while also strengthening support for patients, caregivers, and health systems that are confronted by it,” the researchers wrote.

An analysis of participants in the Black Women’s Health Study explored the relationship between physical activity and quality of life among Black breast cancer survivors.

Researchers sought to determine whether using HRD sources for HSCT would be effective for pediatric patients with hematologic cancers compared with UCB sources.